GILD - Gilead Sciences, Inc
An antiviral drug specialist best known for HIV and hepatitis C treatments, now expanding into oncology and inflammation through acquisitions and internal R&D.
Finlify Score
41.5 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$131.28
-1.09%
52W Range
$108.46 - $157.29
Market Cap
$156.9B
-1.1%Compared to previous day
2026 Q1 Revenue
$7.0B
-12.2%Changes from last reporting quarter
2026 Q1 EPS
$1.61
Diluted shares
Analyst Rating
37 analysts in latest ratings feed
RSI
52.9
40-70 moderate
2Y Range Position
69%
-16.5% from high / +81.3% from low
Beta
0.34
Relative to market benchmark
MACD
-0.09
MACD line 0.66 / signal line 0.74
Fundamental Trend
Growth 35.7Financial Health
Quality 87.6Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID41.5 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $7.0B-12.2% | $7.9B+2.0% | $7.8B+9.7% | $7.1B+6.2% |
| Gross Profit | - | - | - | - |
| Operating Income | $2.6B+30.3% | $2.0B-40.4% | $3.3B+34.5% | $2.5B+10.6% |
| Net Income | $2.0B-7.4% | $2.2B-28.5% | $3.1B+55.7% | $2.0B+49.0% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
Finlify's signal for Gilead Sciences, Inc. (GILD) is 'AVOID', with an overall Finlify Score of 45.1/100, suggesting potential headwinds for the asset.
Technical
Technical indicators appear subdued, with Relative Strength at 30.8/100 and Accumulation / Volume at 32.8/100, which may indicate limited buying interest. While the 20-day return is 4.6% and the 60-day return is 2.4%, the asset is currently 16.0% below its 52-week high, suggesting it may be in a period of consolidation or decline.
Fundamentals
The Fundamental Trend score is relatively low at 35.7/100, which could suggest challenges in underlying business momentum, despite a strong Financial Quality score of 87.6/100. Valuation multiples such as a P/E of 19.0x, P/B of 6.7x, and P/S of 5.5x appear to be at moderate levels, and the asset offers a dividend yield of 2.51% with a low beta of 0.3.
Macro Context
With a low beta of 0.3, GILD may exhibit less sensitivity to broader market fluctuations. However, the current inflationary environment, indicated by CPI YoY at 3.7% and Core PCE YoY at 3.4%, alongside a 10Y Treasury Yield of 4.7%, could influence future growth prospects or the cost of capital for the biotechnology sector.
Key Risks
- Subdued technical scores, with Relative Strength at 30.8/100 and Accumulation / Volume at 32.8/100, may indicate a lack of strong buying momentum.
- The upcoming earnings announcement on 2026-08-06 presents an inherent event risk that could lead to price volatility.
- A low Fundamental Trend score of 35.7/100, despite high financial quality, suggests potential concerns regarding the company's underlying business trajectory.